ST段抬高型心肌梗死患者冠状动脉血栓负担与抗凝及心房颤动危险因素（ATRIA）评分的关系

IF 2.3 4区医学 Q2 HEMATOLOGY

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-22 DOI:10.1177/10760296241237232

Gökhan Coşkun, Cem Ozde, Osman Kayapinar, Gulsah Aktore, Ensar Ekşi, Hamdi Afşin, Ahmet Egemen Sayın

{"title":"ST段抬高型心肌梗死患者冠状动脉血栓负担与抗凝及心房颤动危险因素（ATRIA）评分的关系","authors":"Gökhan Coşkun, Cem Ozde, Osman Kayapinar, Gulsah Aktore, Ensar Ekşi, Hamdi Afşin, Ahmet Egemen Sayın","doi":"10.1177/10760296241237232","DOIUrl":null,"url":null,"abstract":"BackgroundThe anticoagulation and risk factors in atrial fibrillation (ATRIA) score is associated with adverse cardiovascular events. However, its relationship with coronary thrombus burden is unclear. Therefore, we aimed to investigate the relationship between the ATRIA score and thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).Materials and MethodsThe study was designed as a prospective cross-sectional observational study. Our study included 319 patients who were prospectively admitted with STEMI between January 2021 and April 2022. Patients were divided into 2 groups with low thrombus burden (LTB) (grade <3) and high thrombus burden (HTB) (grade ≥3). ATRIA score was calculated and recorded for all patients. ATRIA scores of both groups were compared.ResultsIn our study, 58.9% ( n = 188) of patients in the LTB group and 41% ( n = 131) of patients in the HTB group. The ATRIA risk score ( p < .001) was significantly higher in the HTB group. In multivariate logistic regression analysis, ATRIA score, glomerular filtration rate, hypertensıon, abciximab usage, and no-reflow were found to be independent predictors of HTB in STEMI patients undergoing primary PCI. In receiver operating characteristic analysis, ATRIA score >4 had a sensitivity of 66.2% and specificity of 95.2%, and ATRIA score >8 sensitivity of 98% and specificity of 100% predicted HTB.ConclusionIn this study, we found that thrombus burden may be associated with ATRIA risk score in patients presenting with STEMI.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"19 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction\",\"authors\":\"Gökhan Coşkun, Cem Ozde, Osman Kayapinar, Gulsah Aktore, Ensar Ekşi, Hamdi Afşin, Ahmet Egemen Sayın\",\"doi\":\"10.1177/10760296241237232\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundThe anticoagulation and risk factors in atrial fibrillation (ATRIA) score is associated with adverse cardiovascular events. However, its relationship with coronary thrombus burden is unclear. Therefore, we aimed to investigate the relationship between the ATRIA score and thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).Materials and MethodsThe study was designed as a prospective cross-sectional observational study. Our study included 319 patients who were prospectively admitted with STEMI between January 2021 and April 2022. Patients were divided into 2 groups with low thrombus burden (LTB) (grade <3) and high thrombus burden (HTB) (grade ≥3). ATRIA score was calculated and recorded for all patients. ATRIA scores of both groups were compared.ResultsIn our study, 58.9% ( n = 188) of patients in the LTB group and 41% ( n = 131) of patients in the HTB group. The ATRIA risk score ( p < .001) was significantly higher in the HTB group. In multivariate logistic regression analysis, ATRIA score, glomerular filtration rate, hypertensıon, abciximab usage, and no-reflow were found to be independent predictors of HTB in STEMI patients undergoing primary PCI. In receiver operating characteristic analysis, ATRIA score >4 had a sensitivity of 66.2% and specificity of 95.2%, and ATRIA score >8 sensitivity of 98% and specificity of 100% predicted HTB.ConclusionIn this study, we found that thrombus burden may be associated with ATRIA risk score in patients presenting with STEMI.\",\"PeriodicalId\":10335,\"journal\":{\"name\":\"Clinical and Applied Thrombosis/Hemostasis\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Applied Thrombosis/Hemostasis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10760296241237232\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Applied Thrombosis/Hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10760296241237232","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景心房颤动中的抗凝和危险因素（ATRIA）评分与不良心血管事件有关。然而，其与冠状动脉血栓负荷的关系尚不明确。因此，我们旨在研究接受经皮冠状动脉介入治疗（PCI）的 ST 段抬高型心肌梗死（STEMI）患者的 ATRIA 评分与血栓负荷之间的关系。我们的研究纳入了 2021 年 1 月至 2022 年 4 月期间前瞻性收治的 319 例 STEMI 患者。患者被分为低血栓负荷（LTB）（3级）和高血栓负荷（HTB）（≥3级）两组。计算并记录所有患者的 ATRIA 评分。结果在我们的研究中，LTB 组有 58.9% 的患者（n = 188），HTB 组有 41% 的患者（n = 131）。HTB 组的 ATRIA 风险评分 ( p < .001) 明显高于 LTB 组。在多变量逻辑回归分析中发现，ATRIA 评分、肾小球滤过率、高血压、阿昔单抗的使用和无复流是接受初级 PCI 的 STEMI 患者发生 HTB 的独立预测因素。在接受者操作特征分析中，ATRIA 评分 4 预测 HTB 的敏感性为 66.2%，特异性为 95.2%；ATRIA 评分 8 预测 HTB 的敏感性为 98%，特异性为 100%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction

BackgroundThe anticoagulation and risk factors in atrial fibrillation (ATRIA) score is associated with adverse cardiovascular events. However, its relationship with coronary thrombus burden is unclear. Therefore, we aimed to investigate the relationship between the ATRIA score and thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).Materials and MethodsThe study was designed as a prospective cross-sectional observational study. Our study included 319 patients who were prospectively admitted with STEMI between January 2021 and April 2022. Patients were divided into 2 groups with low thrombus burden (LTB) (grade <3) and high thrombus burden (HTB) (grade ≥3). ATRIA score was calculated and recorded for all patients. ATRIA scores of both groups were compared.ResultsIn our study, 58.9% ( n = 188) of patients in the LTB group and 41% ( n = 131) of patients in the HTB group. The ATRIA risk score ( p < .001) was significantly higher in the HTB group. In multivariate logistic regression analysis, ATRIA score, glomerular filtration rate, hypertensıon, abciximab usage, and no-reflow were found to be independent predictors of HTB in STEMI patients undergoing primary PCI. In receiver operating characteristic analysis, ATRIA score >4 had a sensitivity of 66.2% and specificity of 95.2%, and ATRIA score >8 sensitivity of 98% and specificity of 100% predicted HTB.ConclusionIn this study, we found that thrombus burden may be associated with ATRIA risk score in patients presenting with STEMI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Applied Thrombosis/Hemostasis 医学-外周血管病

CiteScore

4.40

自引率

3.40%

发文量

150

审稿时长

2 months

期刊介绍： CATH is a peer-reviewed bi-monthly journal that addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH covers clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders.